Part ofopioid epidemic →

FEDERALhearing transcript

High Impact

Congressional Hearing on McKinsey & Company's Role in the Opioid Crisis

Original title: MCKINSEY & COMPANY'S CONDUCT AND CONFLICTS AT THE HEART OF THE OPIOID EPIDEMIC

January 1, 2022

opioid epidemic corporate accountability consulting ethics public health congressional oversight

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This hearing investigates the extent of corporate involvement in the opioid epidemic, potentially influencing future federal regulations on consulting firms and pharmaceutical marketing practices.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

McKinsey & Company

The firm is the subject of a congressional investigation regarding its past consulting practices.

Families affected by the opioid epidemic

The committee's investigation is intended to seek accountability for the impact of the opioid crisis on these families.

What changed

Last recorded activity January 1, 2022.

What's next

Next step not available in the current record.

Summary

The House Committee on Oversight and Reform held a hearing to investigate McKinsey & Company's consulting work for opioid manufacturers, specifically regarding strategies used to increase sales of addictive painkillers. The committee examined allegations that the firm advised companies like Purdue Pharma on how to maintain sales despite the rising public health crisis.

Key Facts

The hearing took place on April 27, 2022, before the House Committee on Oversight and Reform.
The committee investigated McKinsey & Company's 15-year history of consulting for opioid manufacturers.
Evidence presented suggests McKinsey advised Purdue Pharma on strategies to 'turbo charge' opioid sales.
In 2017, McKinsey allegedly recommended that Purdue Pharma offer rebates to pharmacy benefit managers for each overdose caused by their opioid products.
The hearing is the third in a series convened by the committee regarding the national opioid epidemic.
Witnesses included McKinsey Global Managing Partner Bob Sternfels and Massachusetts Attorney General Maura Healey.

Frequently Asked Questions

What is the purpose of this hearing?

The hearing aims to promote accountability regarding the opioid epidemic and investigate the role of consulting firms like McKinsey in driving opioid sales.

What specific advice did McKinsey allegedly give to Purdue Pharma?

According to the committee, McKinsey recommended that Purdue Pharma offer s to pharmacy benefit managers for every overdose linked to their opioid pills.

Why It Matters

This hearing investigates the extent of corporate involvement in the opioid epidemic, potentially influencing future federal regulations on consulting firms and pharmaceutical marketing practices.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift80% confidence

Increased Scrutiny of Consulting Firms

The hearing signals a shift toward holding professional service firms accountable for the outcomes of their strategic advice to clients in regulated industries.

McKinsey & Company House Committee on Oversight and Reform

Connected Entities

personCarolyn B. Maloney“Chairwoman of the House Committee on Oversight and Reform”Map →

personSackler family“Owners of Purdue Pharma”Map →

organizationMcKinsey & Company“Consulting firm under investigation for its work with opioid manufacturers”Map →

personBob Sternfels“Global Managing Partner, McKinsey & Company”Map →

organizationPurdue Pharma“Pharmaceutical company that manufactured OxyContin”Map →

personMaura Healey“Attorney General of Massachusetts”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance85
How much this matters to a regular citizen
Controversy80
Intensity of disagreement among stakeholders
Entertainment60
Compellingness for a non-policy-wonk reader
Buzz75
Current news / social attention level

Publisher tools